ImpriMed

ImpriMed is a precision medicine company that specializes in utilizing artificial intelligence (AI) to enhance personalized cancer treatments for pets, primarily dogs and cats. The company pioneered an innovative approach where live cancer cells from the patient are analyzed to measure their response to various anticancer drugs. These drug sensitivity measurements are then combined with other biological data using proprietary AI algorithms to predict the most effective treatment regimens tailored for each individual patient's cancer.

ImpriMed's core offering is the Personalized Prediction Profile service for canine lymphoma and leukemia. This service involves measuring the patient's live cancer cells' responses to chemotherapy drugs like CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and 13 other single-agent drugs. The report provides veterinary oncologists with predictions on the likelihood of response to each drug, expected response timing, and the efficacy probabilities of alternative treatments. As of 2023, over 15,000 such tests have been completed for canine and feline blood cancers.

The company's technology has demonstrated significant real-world results. A 2023 study involving 60 dogs with relapsed B-cell lymphoma treated according to ImpriMed's predictions showed a fourfold higher complete response rate and threefold longer median survival time compared to those treated with lower concordance to the predictions.

ImpriMed is expanding its AI-powered drug response prediction capabilities to human oncology applications, with its software for multiple myeloma prognosis and treatment planned for commercialization in the US in 2025. The company also offers contract research services to pharmaceutical companies, enabling them to evaluate new drug compounds' efficacy using live cancer cells from patients.

Key customers and partnerships

ImpriMed's Personalized Prediction Profile services have been widely adopted by veterinary oncologists across the US. As of 2023, over 350 veterinarians from more than 40 states have utilized the company's services, representing a significant portion of the estimated 600 board-certified veterinary oncologists nationwide.

The company has established strategic partnerships with notable organizations like SK Telecom, a leading South Korean telecommunications company. SK Telecom has developed an AI-based veterinary X-ray image diagnosis technology called X-Caliber, which complements ImpriMed's offerings.

In 2022, ImpriMed graduated from the Mayo Clinic Platform Accelerate Program, where it validated its AI models using a large human patient database provided by the program. This collaboration highlights ImpriMed's focus on translating its expertise from veterinary to human cancer care.